It is perhaps presumptuous of me, but I would like to comment on how I feel. I have routinely seen that treating physicians provide explanations to patients by using the chart known as the “Treatment algorithm for hepatocellular carcinoma” in outpatient treatment rooms. As seen today, the Clinical Practice Guidelines for Hepatocellular Carcinoma have been employed and have become well-known in the clinical setting. In the
conference that I attended, I actually saw how the Clinical Practice Guidelines for Hepatocellular Carcinoma were created and learned that physicians Enzalutamide cost routinely working day and night dealt with an overwhelmingly enormous amount of work for developing the Guidelines (Note: In order to include the
full range of areas, such as prevention, diagnostic imaging, tumor markers, surgical therapy, local aspiration therapy and chemotherapy, physicians who took charge of each special area searched for published work to create a comprehensive collection of BMN-673 evidence and assessed the articles) in addition to their usual medical practices. I realized once again that the physicians’ work was that of professionals and that they are soldiers fighting against hepatocellular carcinoma. A process to thoroughly validate whether a treatment method is evidence-based and whether that evidence is at a level allowing the treatment to be recommended, while taking account of
the degree of the rationale for an index, was exactly the process for building the basis of a treatment policy for patients. The “Clinical Practice Guidelines for Hepatocellular Carcinoma 2009” are designed to provide the best treatment to individual patients in consideration of not only the cancer stage but also the severity Endonuclease of liver damage among many promising treatment methods for hepatocellular carcinoma such as surgical, local and embolization therapies. In particular, the “Treatment algorithm for hepatocellular carcinoma” and the “Surveillance algorithm” are simply and clearly illustrated in figures, and they are easily understandable even for us nurses. I hope that many patients who are currently fighting against hepatocellular carcinoma will be able to use these Guidelines when considering treatment policies, with their physicians and nurses, suitable for each individual. I hope that the Clinical Practice Guidelines for Hepatocellular Carcinoma will be utilized by not only physicians but also by nurses at many medical institutions. May 2009 Kayo Nojiri, Department of Nursing, University of Tokyo Hospital, Tokyo, Japan “
“In a recent article published in Gastroenterology, Carpentier et al.1 suggested that embryonic ductal plate cells give rise to cholangiocytes, periportal hepatocytes, and adult liver progenitor cells.